αcd3 αcd28 antibody conjugated beads

Autologous T cells were manufactured from patient derived apheresis at either Cell and Vaccine Production Facility at the University of Pennsylvania or at Progenitor Cell Therapy. CD25-depleted CD4+ and CD8 + T cells were activated and expanded using αCD3/αCD28 antibody-conjugated beads (Life Technologies) and then used to develop the engineered T cells. T cells were transduced with a self-inactivating lentivirus vector, derived from HIV-1 containing a woodchuck hepatitis virus posttranscriptional regulatory element, at a multiplicity of infection of 1 transducing unit per cell. T cell manufacturing time ranged from 28 to 35 days, including release testing. Transduction potency was measured on primary T cells.

Briefly, engineered T cells were manufactured at the Cell and Vaccine Production Facility at the University of Pennsylvania (Philadelphia, PA) for patients 201 and 202. The remaining patients’ cells were manufactured at Hitachi Chemical Advanced Therapeutics Solutions LLC (Allendale, NJ). Engineered T cells were generated from CD3⁺ T cells that were activated and expanded using αCD3/αCD28 antibody-conjugated beads (Life Technologies). T cells were transduced at a target multiplicity of infection of 1 transducing unit per cell.